{"id":"NCT00316719","sponsor":"GlaxoSmithKline","briefTitle":"Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients","officialTitle":"Phase III Study of Adefovir Dipivoxil Tablets in Patients With Compensated Chronic Hepatitis B -Comparative Study Against Lamivudine-","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2006-04-21","resultsPosted":"2009-08-03","lastUpdate":"2009-10-06"},"enrollment":105,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis B"],"interventions":[{"type":"DRUG","name":"LAM group","otherNames":["Lamivudine"]},{"type":"DRUG","name":"ADV group","otherNames":["adefovir dipivoxil"]}],"arms":[{"label":"Adefovir Dipivoxil (ADV)","type":"EXPERIMENTAL"},{"label":"Lamivudine (LAM)","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to compare the efficacy and safety of adefovir dipivoxil 10 mg with lamivudine 100 mg in Japanese patients with compensated chronic hepatitis B over 52-week periods.","primaryOutcome":{"measure":"Mean Change From Baseline in Hepatitis B Virus (HBV) DNA at Week 52","timeFrame":"Baseline and Week 52","effectByArm":[{"arm":"Adefovir (ADV)","deltaMin":-3.69,"sd":1.169},{"arm":"Lamivudine (LAM)","deltaMin":-3.4,"sd":1.896}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Diarrhea","Blood creatine phosphokinase increased","Eczema"]}}